Tty Biopharm Company Limited · TPEX:4105
Tty Biopharm — FY2025 Earnings Presentation
16 slides from Tty Biopharm's earnings presentation, Mar 25, 2026
Slide 1: TTY Biopharm 2025 Operational Results Report
TTY Biopharm 4105 2025 Operational Results Report 2026.03.25
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, TTY Biopharm cautions that this foregoing list of factors is not ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’,
Slide 3: Operational Highlights
Operational Results Report 2025 Operational Highlights 2025 Financial Performance 01 2025 Operational Highlights 2026 Outlook 2
Slide 4: TTY Strategy Enhances Operational Performance
TTY Strategy Enhances Operational Performance Operational Results Report Revenue Overview 2025 Operational Unit：Million Highlights Consolidated Revenue 7,000 6,453 7 YoY growth +9.5% 6.45 billion 5,894 6.27 6,000 6 2025 Financial 5,000 5.83 Performance 5 4,000 4 Consolidated Operating Profit 3,000 2
Slide 5: Market Development Highlights
Market Development Highlights Operational Results Report 2025 Operational Highlights 2025 Financial Performance 2026 Outlook Strong growth in overseas sales Significant Achievements in Self- Flu vaccine sales driven both public & private funded Developed and Domestically Lipo-AB's sales in the US is
Slide 6: Export Share of Operations
Export Share of Operations Operational Unit：Million Results Report 1,200.0 YoY +24.5% YoY +46.2% Overseas revenue with an annual growth rate of 24.5% 962.7 2024 2025 1,000.0 US market with an annual growth rate of 46.2%. 773.1 800.0 2025 557.5 Operational 600.0 Highlights 381.3 400.0 200.0 2025 0.0
Slide 7: Three Arrows of Operation with Outstanding Results
Three Arrows of Operation with Outstanding Results Operational Results Report 2025 Operational Highlights 2025 Financial Performance 2026 Outlook 6
Slide 8: Product Pipeline: Self-develop, License-in, Cooperation
Product Pipeline: Self-develop, License-in, Cooperation Operational Results Report Oncology 2025 2026 2027 2028 2029 Pulmivex XPOVIO 2025 T1502 Operational Highlights T1508 T5260 T1509/T3505 2025 Financial Performance Intensive Care 2025 2026 2027 2028 TTY_2D（Skin tissue infections and bacteremia ca
Slide 9: Financial Performance
Operational Results Report 2025 Operational Highlights 2025 Financial Performance 02 2025 Financial Performance 2026 Outlook 8
Slide 10: 2025 Financial Performance
2025 Financial Performance Operational Results Report Income Statement YoY YoY （Unit: NT Thousand, 2025 2024 Differences % Financial Performance except EPS） 2025 Net Sales 6,452,948 5,893,847 559,101 9.5% • YoY consolidated revenue was 6.45 billion, +9.5% Operational due to the high growth of overse
Slide 11: 2025 Steady Revenue Growth
2025 Steady Revenue Growth Operational Results Report 2025 Revenue Breakdown 2025 Revenue Growth 2025 Operational Highlights Product Category % Revenue (NT Mn) 38 4 -31 6,400 113 6,453 20.7% 211 Oncology 6,200 2025 Financial 37.8% 3.0% 224 Intensive Care 6,000 Performance Healthcare 5,800 5,894 13.9
Slide 12: 2025 Key Performance
2025 Key Performance Operational Results Report Revenue Unit: USD Million Excellent Performance 210 • TOP 5% of TPEx-listed companies in the Company 2025 Governance Evaluation. Operational Highlights 140 • In 2025, the company reached a record-high net profit of NTD 1,559 million (USD 49.9 million),
Slide 13: 2026 Outlook
Operational Results Report 2025 Operational Highlights 2025 Financial Performance 03 2026 Outlook 2026 Outlook 12
Slide 14: 2026 Outlook
2026 Outlook Operational Results Report 1 • Lipo-AB: -Expected to obtain licenses from Saudi Arabia, Australia, and Jordan -Deploy the market in Southeast Asia and South 2025 Expanding collaboration & America Operational • Leavdo launched in Singapore Highlights overseas market • Continue to cultiva
Slide 15: Vaccine Field
Vaccine Field Operational Results Report Comprehensive vaccine portfolio to support public health Create an all-age influenza vaccine product line and become the market leader 2025 Operational Trivalent Trivalent Quadrivalent Highlights cell & adjuvanted influenza vaccine adjuvanted influenza vaccin
Slide 16: OkaBIK Varicella Vaccine
OkaBIK Varicella Vaccine Operational Results Report First approved in Japan in The varicella vaccine is a 2025 routine vaccine, with the Operational 1984, it has been used for first dose subsidized by the Highlights 40 years. government. Currently, most varicella vaccines used worldwide Bidding will